IN8bio (INAB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Mar, 2026Executive summary
Annual meeting scheduled for May 7, 2026, to be held virtually for shareholders of record as of March 18, 2026.
Shareholders will vote on director elections, auditor ratification, and an equity incentive plan.
Voting matters and shareholder proposals
Election of two Class II directors, Peter Brandt and Corinne Epperly, to serve until the 2029 annual meeting.
Ratification of CohnReznick LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Approval of the Amended and Restated 2026 Equity Incentive Plan.
Board of directors and corporate governance
Two nominees for Class II director positions are presented for election, with terms extending to 2029.
Partial view of Summaries dataset, powered by Quartr API
Latest events from IN8bio
- Net loss narrowed to $4.8M in Q2 2026; DeltEx DRI in GBM achieved >19.5 months mOS.INAB
Q2 2026 - γδ T cell therapies show strong efficacy and safety in cancer and autoimmune trials, with key 2026 milestones ahead.INAB
Corporate presentation - Repeat dosing of gamma-delta T cell therapies yields strong survival and immune benefits in GBM.INAB
R&D Day 2026 - Biopharma innovator targets $200M shelf offering for cell therapy pipeline amid going concern risk.INAB
Registration filing - Net loss narrowed to $5.1M in Q1 2026; strong GBM data and limited cash runway.INAB
Q1 2026 - Gamma delta T cell therapies and novel engagers show strong efficacy and safety, with major milestones ahead.INAB
Biotech Resurgence: Platforms and Pipelines of Today's Innovators - Annual meeting to vote on director elections, auditor ratification, and expanded equity plan.INAB
Proxy filing - Durable remissions and superior safety achieved with γδ T cell therapies in oncology trials.INAB
Investor presentation - Clinical progress in glioblastoma and improved financials set up key milestones for 2026.INAB
Q4 2025